by Bonnell Foundation | May 8, 2012 | Featured, News
Parents who have kids with the deltaF508 strain of cystic fibrosis will soon be able to breathe a little easier. Results from the clinical trials by Vertex Pharmaceutical’s have stocks climbing. The drug company climbed 55 percent to $58.12 at the close of the New...
